Sarepta Elevidys FDA Challenges

News

FDA, Sarepta and Elevidys

FDA Probes Death of 8-Year-Old Linked to Sarepta’s Elevidys Gene Therapy

The U.S. Food and Drug Administration (FDA) is investigating the death of an eight-year-old boy who received Sarepta Therapeutics (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD).

· 6d

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

Devdiscourse · 8d

FDA Scrutiny Intensifies as Sarepta Gene Therapy Faces Dire Setbacks

5don MSN

Sarepta’s Elevidys Halted at Children’s Hospital Los Angeles

Children’s Hospital Los Angeles paused the use of Sarepta Therapeutics Inc.’s gene therapy for Duchenne muscular dystrophy in ...

4don MSN

Sarepta pares gains as report suggests an ‘arduous’ path for Duchenne drug

Sarepta Therapeutics (NASDAQ:SRPT) faces an “arduous and treacherous path” to bring its gene therapy Elevidys back to market, ...

FiercePharma1mon

FDA investigates patient deaths after treatment with Sarepta's Duchenne ...

FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys By Angus Liu Jun 25, 2025 10:26am Sarepta Therapeutics gene therapy U.S. FDA FDA investigation ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results